Comparison of effects of isoniazid plus ART and ART only regimen on the incidence of tuberculosis and HIV progression in HIV positive patients: a retrospective cohort study at two hospitals in Addis Ababa, Ethiopia
Journal: International Journal of Basic & Clinical Pharmacology (Vol.3, No. 1)Publication Date: 2014-02-01
Authors : Dumessa Edessa Tolera Woldeyes Workineh Shibeshi;
Page : 54-62
Keywords : Antiretroviral therapy; HIV-infected; Tuberculosis; Isoniazid preventive therapy;
Abstract
Background: Tuberculosis is a major opportunistic complication of HIV-infection. Antiretroviral therapy (ART) lowers incidence of tuberculosis (TB) but may not be sufficient to control HIV-related tuberculosis, implying a need for additional interventions. The aim of this study was to compare the effects of isoniazid preventive therapy (IPT) plus ART and ART only regimens on the incidence of active TB and HIV progression in HIV positive patients. Methods: The retrospective cohort study was conducted at Tikur Anbessa Specialized Hospital and Zewditu Memorial Hospital on 185 patients receiving IPT plus ART and 557 patients receiving ART only. Incidence rates (IR) were used to determine incidence rates of tuberculosis. Time to AIDS and TB event were compared using student t-test. Risks of the outcomes were identified using regression models. Results: The study showed a reduced tuberculosis incidence rate from 7.44 to 1.8 cases/100 person-years [PYs] by IPT plus ART compared to ART only. In reference to ART alone, the IPT plus ART significantly reduced risks of active TB (adjusted odds ratio [AOR] 0.24; 95% CI 0.09?0.63; P=0.004) and had about 16 months of TB protection.
Other Latest Articles
- Knowledge, attitude and practice of pharmacovigilance among private healthcare professionals of Rajkot city
- Factors determinant for change of initial antiretroviral treatment regimen among patients on ART follow-up clinic of Mekelle Hospital, Mekelle, Ethiopia
- Advances in human papilloma virus vaccines: a review
- Histone deacetylase inhibitors: pharmacotherapeutic implications as epigenetic modifier
- Angiogenesis inhibitors in cancer therapeutics
Last modified: 2014-02-08 14:03:16